Clinical Trial

An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA U CAR T cell injection (KN3601) in patients with Relapsed/Refractory immune-mediated kidney disease
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2026-02-05
Trial Details
NCT Number NCT07241468
Lead Sponsor Changhai Hospital
Collaborators: Rui Therapeutics Co., Ltd
Conditions Relapsed/Refractory Immune Nephropathy, Relapsed/Refractory Immune-mediated Kidney Disease
Enrollment 36 participants
Start Date 2025-11-15
Primary Completion 2026-12-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-06